Listen "FDA Approval: Maintenance Lurbinectedin for SCLC"
Episode Synopsis
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of maintenance lurbinectedin plus atezolizumab for extensive stage small cell lung cancer, based on the phase III IMforte trial. Dr. Hossein Borghaei joins the podcast to explain the results and offer perspective on the impact of maintenance therapy for SCLC.
Guest:
Dr. Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Guest:
Dr. Hossein Borghaei, DO, MS
Chief, Division of Thoracic Medical Oncology
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
More episodes of the podcast Lung Cancer Considered
LCC in Georgian: WCLC 2025 Highlights
07/11/2025
LCC in Hungarian: WCLC 2025 Highlights
31/10/2025
LCC in Greek: WCLC 2025 Highlights
10/10/2025
LCC in Arabic: WCLC 2025 Highlights
03/10/2025
Lung Cancer Considered: Targeting EGFR NSCLC
03/10/2025
ZARZA We are Zarza, the prestigious firm behind major projects in information technology.